[{"address1": "Carl Jacobsens Vej 30", "address2": "Valby", "city": "Copenhagen", "zip": "2500", "country": "Denmark", "phone": "45 70 20 27 28", "website": "https://www.genmab.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.", "fullTimeEmployees": 2973, "companyOfficers": [{"maxAge": 1, "name": "Dr. Jan G.J. van de Winkel Ph.D.", "age": 64, "title": "Co-Founder, President & CEO", "yearBorn": 1961, "fiscalYear": 2025, "totalPay": 3300000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Rayne  Waller", "age": 57, "title": "Executive VP & Chief Technical Operations Officer", "yearBorn": 1968, "fiscalYear": 2025, "totalPay": 1800000, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1767139200, "irWebsite": "http://ir.genmab.com/index.cfm", "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 28.9, "open": 29.04, "dayLow": 28.94, "dayHigh": 29.485, "regularMarketPreviousClose": 28.9, "regularMarketOpen": 29.04, "regularMarketDayLow": 28.94, "regularMarketDayHigh": 29.485, "payoutRatio": 0.0, "beta": 0.795, "trailingPE": 12.846492, "forwardPE": 16.185183, "volume": 2085873, "regularMarketVolume": 2085873, "averageVolume": 1609855, "averageVolume10days": 1288960, "averageDailyVolume10Day": 1288960, "bid": 29.25, "ask": 29.35, "bidSize": 1, "askSize": 1, "marketCap": 18042437632, "fiftyTwoWeekLow": 17.235, "fiftyTwoWeekHigh": 35.43, "allTimeHigh": 103.19, "allTimeLow": 0.654, "priceToSalesTrailing12Months": 4.8501177, "fiftyDayAverage": 32.3472, "twoHundredDayAverage": 27.0791, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 5515820544, "profitMargins": 0.25887, "floatShares": 60900525, "sharesOutstanding": 615993070, "sharesShort": 8413829, "sharesShortPriorMonth": 11130671, "sharesShortPreviousMonthDate": 1767139200, "dateShortInterest": 1769731200, "sharesPercentSharesOut": 0.0137, "heldPercentInsiders": 0.00018999999, "heldPercentInstitutions": 0.12113, "shortRatio": 4.18, "shortPercentOfFloat": 0.0138, "impliedSharesOutstanding": 615993070, "bookValue": 94.89, "priceToBook": 0.3086732, "lastFiscalYearEnd": 1767139200, "nextFiscalYearEnd": 1798675200, "mostRecentQuarter": 1767139200, "earningsQuarterlyGrowth": -0.946, "netIncomeToCommon": 963000000, "trailingEps": 2.28, "forwardEps": 1.80968, "lastSplitFactor": "5:1", "lastSplitDate": 1525132800, "enterpriseToRevenue": 1.483, "enterpriseToEbitda": 4.276, "52WeekChange": 0.37942123, "SandP52WeekChange": 0.11527538, "quoteType": "EQUITY", "currentPrice": 29.29, "targetHighPrice": 48.0, "targetLowPrice": 24.5, "targetMeanPrice": 37.94444, "targetMedianPrice": 38.5, "recommendationMean": 1.66667, "recommendationKey": "buy", "numberOfAnalystOpinions": 9, "totalCash": 1715000064, "totalCashPerShare": 27.832, "ebitda": 1290000000, "totalDebt": 5425999872, "quickRatio": 2.009, "currentRatio": 2.022, "totalRevenue": 3720000000, "debtToEquity": 92.8, "revenuePerShare": 5.9854, "returnOnAssets": 0.08101, "returnOnEquity": 0.17535, "grossProfits": 3481999872, "freeCashflow": 1068124992, "operatingCashflow": 1186000000, "earningsGrowth": -0.944, "revenueGrowth": 0.03, "grossMargins": 0.93601996, "ebitdaMargins": 0.34677, "operatingMargins": 0.22968, "financialCurrency": "USD", "symbol": "GMAB", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "firstTradeDateMilliseconds": 1243863000000, "postMarketChangePercent": -0.9901021, "postMarketPrice": 29.0, "postMarketChange": -0.29000092, "regularMarketChange": 0.390001, "regularMarketDayRange": "28.94 - 29.485", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 1609855, "fiftyTwoWeekLowChange": 12.055, "fiftyTwoWeekLowChangePercent": 0.69944876, "fiftyTwoWeekRange": "17.235 - 35.43", "fiftyTwoWeekHighChange": -6.1399994, "fiftyTwoWeekHighChangePercent": -0.17329945, "fiftyTwoWeekChangePercent": 37.942123, "corporateActions": [], "postMarketTime": 1771635055, "regularMarketTime": 1771621202, "exchange": "NMS", "messageBoardId": "finmb_665704", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 1.34949, "regularMarketPrice": 29.29, "earningsTimestamp": 1771362000, "earningsTimestampStart": 1778187600, "earningsTimestampEnd": 1778187600, "earningsCallTimestampStart": 1771347600, "earningsCallTimestampEnd": 1771347600, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": 2.28, "epsForward": 1.80968, "epsCurrentYear": 1.0212, "priceEpsCurrentYear": 28.681946, "fiftyDayAverageChange": -3.0571976, "fiftyDayAverageChangePercent": -0.09451197, "twoHundredDayAverageChange": 2.2109013, "twoHundredDayAverageChangePercent": 0.08164604, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.7 - Buy", "cryptoTradeable": false, "marketState": "CLOSED", "shortName": "Genmab A/S", "longName": "Genmab A/S", "hasPrePostMarketData": true, "trailingPegRatio": 0.5817, "__fetch_time": "2026-02-21"}]